Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial.

Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middeke JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M, Zoephel K.

Haematologica. 2019 Aug 29. pii: haematol.2019.223032. doi: 10.3324/haematol.2019.223032. [Epub ahead of print]

2.

Parvovirus B19 Infection.

Mende M, Sockel K.

N Engl J Med. 2018 Dec 13;379(24):2361. doi: 10.1056/NEJMicm1807156. No abstract available.

3.

Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Sockel K, Platzbecker U.

Drugs. 2018 Dec;78(18):1873-1885. doi: 10.1007/s40265-018-1011-6. Review.

PMID:
30467725
4.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
5.

A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.

Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Béné MC, Platzbecker U, Eveillard M.

Br J Haematol. 2018 Dec;183(5):736-746. doi: 10.1111/bjh.15626. Epub 2018 Nov 8.

PMID:
30406952
6.

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Middeke JM, Kollinger F, Baldauf H, Stölzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Röllig C, Thiede C, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1947-1951. doi: 10.1016/j.bbmt.2018.05.021. Epub 2018 May 21.

7.

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group.

Br J Haematol. 2019 Mar;184(5):833-836. doi: 10.1111/bjh.15181. Epub 2018 Mar 12. No abstract available.

PMID:
29528122
8.

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U.

Leukemia. 2017 Oct;31(10):2247-2251. doi: 10.1038/leu.2017.217. Epub 2017 Jul 10. No abstract available.

PMID:
28690314
9.

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.

10.

Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.

Büttner B, Knoth H, Kramer M, Oertel R, Seeling A, Sockel K, von Bonin M, Stölzel F, Alakel N, Platzbecker U, Röllig C, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM.

Leuk Lymphoma. 2017 Dec;58(12):2865-2874. doi: 10.1080/10428194.2017.1319051. Epub 2017 May 16.

PMID:
28509593
11.

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient.

Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Röllig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2017 Jul;31(7):1637-1640. doi: 10.1038/leu.2017.104. Epub 2017 Mar 28. No abstract available.

PMID:
28348390
12.

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.

von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M.

Stem Cells. 2016 Feb;34(2):357-66. doi: 10.1002/stem.2224. Epub 2015 Oct 13.

13.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18.

PMID:
26283567
14.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

15.

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

Oelschlaegel U, Alexander Röhnert M, Mohr B, Sockel K, Herold S, Ehninger G, Bornhäuser M, Thiede C, Platzbecker U.

Leukemia. 2016 Feb;30(2):517-20. doi: 10.1038/leu.2015.158. Epub 2015 Jun 24. No abstract available.

16.

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, Thiede C, Bornhäuser M, Ehninger G, van de Loosdrecht AA, Platzbecker U.

Haematologica. 2015 Mar;100(3):e93-6. doi: 10.3324/haematol.2014.115725. Epub 2014 Nov 25. No abstract available.

17.

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.

Platzbecker U, Sockel K, Schönefeldt C, Nowak D, Helas S, Röllig C, Mossner M, Jann JC, Ehninger G, Hofmann WK, Bornhäuser M, Thiede C, Wermke M.

Haematologica. 2014 Dec;99(12):e247-8. doi: 10.3324/haematol.2014.111948. Epub 2014 Sep 5. No abstract available.

18.

When to transplant MDS, and what to do when transplant fails.

Sockel K, Platzbecker U.

Curr Hematol Malig Rep. 2013 Dec;8(4):379-85. doi: 10.1007/s11899-013-0181-2. Review.

PMID:
24091832
19.

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation.

Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Oelschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M.

Blood Cancer J. 2013 Aug 30;3:e136. doi: 10.1038/bcj.2013.35. No abstract available.

20.

Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow.

Neukirchen J, Platzbecker U, Sockel K, Tsamaloukas A, Haas R, Germing U.

Ann Hematol. 2014 Jan;93(1):65-9. doi: 10.1007/s00277-013-1859-1. Epub 2013 Aug 10.

PMID:
23934199
21.

Is it already time for combination treatment in lower risk MDS?

Sockel K, Platzbecker U.

Chin Clin Oncol. 2012 Dec;1(2):23. doi: 10.3978/j.issn.2304-3865.2012.12.02. No abstract available.

22.

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schönefeldt C, Mair S, Plodeck V, Laniado M, Weiss G, Schetelig J, Ehninger G, Theurl I, Bornhäuser M, Platzbecker U.

Clin Cancer Res. 2012 Dec 1;18(23):6460-8. doi: 10.1158/1078-0432.CCR-12-1683. Epub 2012 Sep 18.

23.

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Greiner J, Beelen D, Thiede C, Ehninger G, Platzbecker U; German MDS and Cooperative Transplant Study Group (GCTSG).

Haematologica. 2012 Sep;97(9):e34-5. No abstract available.

24.

Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.

Sockel K, Ehninger G, Hofbauer LC, Platzbecker U.

Expert Rev Hematol. 2011 Dec;4(6):669-80. doi: 10.1586/EHM.11.58. Review.

PMID:
22077530
25.

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, Ehninger G, Thiede C, Platzbecker U.

Haematologica. 2011 Oct;96(10):1568-70. doi: 10.3324/haematol.2011.044388. Epub 2011 Jul 12. No abstract available.

26.

Hip pain in medulloblastoma as first symptom of extraneural relapse.

Sockel K, Ordemann R, von Bonin M, Jahn S, Prange-Krex G, Ehninger G, Kroschinsky F.

Onkologie. 2011;34(4):196-8. doi: 10.1159/000327002. Epub 2011 Mar 23. No abstract available.

PMID:
21447979

Supplemental Content

Loading ...
Support Center